Brain delivery of proteins via their fatty acid and block copolymer modifications

Journal of Drug Targeting

Volumn 21, Issue 10, 2013, Pages 940-955

  Yi, Xiang ^a   Kabanov, Alexander V ^a,b  

^a University of North Carolina   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Blood brain barrier; Brain delivery; Copolymer; Drug delivery; Peptide; Pharmacokinetics; Polymer

Indexed keywords

ALPHA INTERFERON; ALPHA INTERMEDIN; ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; COPOLYMER; COPPER ZINC SUPEROXIDE DISMUTASE; FATTY ACID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HORSERADISH PEROXIDASE; LEPTIN; MACROGOL; OCTANOIC ACID; PANCREAS POLYPEPTIDE; PEGADEMASE; PEGAPTANIB; PEGINESATIDE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PEGVISOMANT; POLOXAMER; POLYCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STREPTOKINASE; UNINDEXED DRUG; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; ACYLATION; ANEMIA; ANTIVIRAL ACTIVITY; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL MEMBRANE; CELL MIGRATION; CHEMOTHERAPY INDUCED NEUTROPENIA; CIRCULATION TIME; CONJUGATION; CROHN DISEASE; DRUG EFFICACY; DRUG TARGETING; ENERGY EXPENDITURE; ENZYME INACTIVATION; FOOD INTAKE; GEL PERMEATION CHROMATOGRAPHY; GOUT; HEPATITIS C; HUMAN; MICELLE; NEUTROPENIA; NONHUMAN; PLASMA HALF LIFE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; PROTEIN TRANSPORT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVERSE MICELLE; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SOLID PHASE SYNTHESIS; UNITED STATES; USSR; VIRUS HEPATITIS;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; FATTY ACIDS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; POLYMERS; PROTEINS; TISSUE DISTRIBUTION;

EID: 84887223983     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.847098     Document Type: Review

References (135)

1. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 2009;87:212-51.
2. Boer AG, Gaillard PJ. Drug targeting to the brain. Ann Rev Pharmacol Toxicol 2007;47:323-55.
3. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37: 48-57.
4. Lichota J, Skjorringe T, Thomsen LB, Moos T. Macromolecular drug transport into the brain using targeted therapy. J Neurochem 2010;113:1-13.
5. Thorne RG, Frey II WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinetics 2001;40:907-46.
6. Dhuria SV, Hanson LR, Frey II WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73.
7. Landis MS, Boyden T, Pegg S. Nasal-to-cns drug delivery: where are we now and where are we heading? An industrial perspective. Ther Deliv 2012;3:195-208.
8. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614-28.
9. Merkus FW, van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs R&D 2007;8:133-44.
10. Watts RJ, Dennis MS. Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol 2013;17:393-9.
11. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Translational Med 2011;84:44-51.
12. Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 2009;1:463-74.
13. Gilmore JL, Yi X, Quan L, Kabanov AV. Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol 2008;3: 83-94.
14. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polymer Sci 2007;32: 1054-82.
15. Tiwari SB, Amiji MM. A review of nanocarrier-based cns delivery systems. Curr Drug Deliv 2006;3:219-32.
16. Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release 2007;122:1-9.
17. Tosi G, Vergoni AV, Ruozi B, et al. Sialic acid and glycopeptides conjugated plga nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release 2010;145:49-57.
18. Tosi G, Bortot B, Ruozi B, et al. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr Med Chem 2013;20:2212-25.
19. Townsend SA, Evrony GD, Gu FX, et al. Tetanus toxin c fragmentconjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 2007;28:5176-84.
20. Vergoni AV, Tosi G, Tacchi R, et al. Nanoparticles as drug delivery agents specific for cns: In vivo biodistribution. Nanomedicine 2009; 5:369-77.
21. Magee T, Seabra MC. Fatty acylation and prenylation of proteins: what's hot in fat. Curr Opinion Cell Biol 2005;17:190-6.
22. Nadolski MJ, Linder ME. Protein lipidation. FEBS J 2007;274: 5202-10.
23. Resh MD. Trafficking and signaling by fatty-Acylated and prenylated proteins. Nat Chem Biol 2006;2:584-90.
24. Smotrys JE, Linder ME. Palmitoylation of intracellular signaling proteins: regulation and function. Ann Rev Biochem 2004;73: 559-87.
25. Torchilin VP, Klibanov AL. Immobilization of proteins on liposome surface. Enzyme Microb Technol 1981;3:297-304.
26. Chekhonin VP, Kabanov AV, Zhirkov YA, Morozov GV. Fatty acid acylated fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain. FEBS Lett 1991; 287:149-52.
27. Kabanov AV, Levashov AV, Martinek K. Transformation of watersoluble enzymes into membrane active form by chemical modification. Annals N Y Acad Sci 1987;501:63-6.
28. Kabanov AV, Levashov AV, Alakhov V. Lipid modification of proteins and their membrane transport. Protein Eng 1989;3:39-42.
29. Slepnev VI, Phalente L, Labrousse H, et al. Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells. Bioconjug Chem 1995;6:608-15.
30. Chopineau J, Robert S, Fenart L, et al. Monoacylation of ribonuclease a enables its transport across an in vitro model of the blood-brain barrier. J Control Release 1998;56:231-7.
31. Batrakova EV, Vinogradov SV, Robinson SM, et al. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem 2005;16: 793-802.
32. Lasarev AP, Sukharev OI, Gruzdev KN, et al. Bioactive preparation for pigs, method of its preparing, method of prophylaxis and treatment of viral disease in pigs. RU 2058789 C1. Russian; 1996.
33. Levashov AV, Kabanov AV, Khmelnitskii Yu L, et al. Chemical modification of proteins (enzymes) by water-insoluble reagents. Doklady Akademii Nauk SSSR 1984;278:246-8.
34. Severin ES, Melik-Nubarov NS, Ovcharenko AV, et al. Hydrophobized antiviral antibodies and antisense oligonucleotides. Adv Enzyme Regul 1991;31:417-30.
35. Kabanov A. Enhancement of macromolecule penetration into cells and nontraditional drug delivery systems. Soviet Scientific Reviews Series, Section D. Switzerland: Taylor &Francis Group; 1992.
36. Alakhov V, Kabanov AV, Batrakova EV, et al. Increasing cytostatic effects of ricin a chain and staphylococcus aureus enterotoxin a through in vitro hydrophobization with fatty acid residues. Biotechnol Appl Biochem 1990;12:94-8.
37. Kabanov AV, Ovcharenko AV, Melik-Hubarov NS, et al. Fatty acid acylated antibodies against virus suppress its reproduction in cells. FEBS Lett 1989;250:238-40.
38. Yuan L, Wang J, Shen WC. Lipidization of human interferon-Alpha: a new approach toward improving the delivery of protein drugs. J Control Release 2008;129:11-17.
39. Bellmann-Sickert K, Elling CE, Madsen AN, et al. Long-Acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J Med Chem 2011;54:2658-67.
40. Banks WA, Tschop M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002;302:822-7.
41. Bednarek MA, Feighner SD, Pong SS, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000;43: 4370-6.
42. Chen CY, Fujimiya M, Asakawa A, et al. At the cutting edge: Ghrelin gene products in food intake and gut motility. Neuroendocrinology 2009;89:9-17.
43. Horvath TL, Diano S, Sotonyi P, et al. Minireview: ghrelin and the regulation of energy balance-A hypothalamic perspective. Endocrinology 2001;142:4163-9.
44. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature 1999;402:656-60.
45. Garber AJ. Long-Acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34: S279-84.
46. Jespersen MJ, Knop FK, Christensen M. Glp-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2013;9:17-29.
47. Kanoski SE, Fortin SM, Arnold M, et al. Peripheral and central glp-1 receptor populations mediate the anorectic effects of peripherally administered glp-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011;152:3103-12.
48. Conde-Frieboes K, Thogersen H, Lau JF, et al. Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (mc4-r) selective alpha-melanocyte-stimulating hormone (alpha-msh) analogues. J Med Chem 2012;55:1969-77.
49. Wulff BS. Safety and efficacy of a long-Acting alpha-msh analogue, mc4-nn2-0453, in overweight to obese but otherwise healthy subjects. Keystone Symposia on Molecular and Cellular Biology, Neuronal Control of Appetite, Metabolism and Weight; 2013; Fairmont Banff Springs, Banff, Alberta, Canada.
50. Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat Rev Drug Discov 2008;7:241-54.
51. Barsh GS, Schwartz MW. Genetic approaches to studying energy balance: perception and integration. Nat Rev Genet 2002;3: 589-600.
52. Boughton CK, Murphy KG. Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. Brit J Pharmacol 2012. [Epub ahead of print]. doi: 10.1111/bph.12037.
53. McGavigan AK, Murphy KG. Gut hormones: the future of obesity treatment? Brit J Clin Pharmacol 2012;74:911-19.
54. Vasselli JR, Scarpace PJ, Harris RB, Banks WA. Dietary components in the development of leptin resistance. Adv Nutr 2013;4:164-75.
55. Colon-Gonzalez F, Kim GW, Lin JE, et al. Obesity pharmacotherapy: what is next? Mol Aspects Med 2013;34:71-83.
56. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Ann Rev Pharmacol Toxicol 2007;47:565-92.
57. Holst JJ. The physiology of glucagon-like peptide Physiological Rev 2007;87:1409-39.
58. Maletinska L, Nagelova V, Ticha A, et al. Lipidated analogs of prolactin-releasing peptide decrease food intake after peripheral administration. Keystone Symposia on Molecular and Cellular Biology, Neuronal Control of Appetite, Metabolism and Weight; 2012; Fairmont Banff Springs, Banff, Alberta, Canada.
59. Edmond J, Higa TA, Korsak RA, et al. Fatty acid transport and utilization for the developing brain. J Neurochem 1998;70: 1227-34.
60. Edmond J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci 2001;16:181-93; discussion 215-21.
61. Vangaveti V, Shashidhar V, Jarrod G, et al. Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Ther Adv Endocrinol Metabol 2010;1:165-75.
62. Ma D, Lu L, Boneva NB, et al. Expression of free fatty acid receptor gpr40 in the neurogenic niche of adult monkey hippocampus. Hippocampus 2008;18:326-33.
63. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010;99:2557-75.
64. Duncan R, Gilbert HR, Carbajo RJ, Vicent MJ. Polymer maskedunmasked protein therapy. Bioresponsive dextrin-trypsin and-melanocyte stimulating hormone conjugates designed for alphaamylase activation. Biomacromolecules 2008;9:1146-54.
65. Ferguson EL, Duncan R. Dextrin-phospholipase a2: synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules 2009;10:1358-64.
66. Hardwicke J, Ferguson EL, Moseley R, et al. Dextrin-rhegf conjugates as bioresponsive nanomedicines for wound repair. J Control Release 2008;130:275-83.
67. Hardwicke J, Moseley R, Stephens P, et al. Bioresponsive dextrinrhegf conjugates: in vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds. Mol Pharm 2010; 7:699-707.
68. Oh EJPK, Kim KS, Kim J, et al. Target specific and long-Acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010;141:2-12.
69. Kopecek J, Kopeckova P. Hpma copolymers: Origins, early developments, present, and future. Adv Drug Deliv Rev 2009;62: 122-49.
70. Chapman AP. Pegylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54:531-45.
71. Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002;54: 457-8.
72. Hinds KD, Kim SW. Effects of peg conjugation on insulin properties. Adv Drug Deliv Rev 2002;54:505-30.
73. Kinstler O, Molineux G, Treuheit M, et al. Mono-n-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002;54:477-85.
74. Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 kd) (pegasys) for the treatment of hepatitis c. Adv Drug Deliv Reviews 2002;54:571-86.
75. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein pegylation. Adv Drug Deliv Rev 2002;54:459-76.
76. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002;54:487-504.
77. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 2002;54:587-606.
78. Veronese FM, Harris JM. Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 2002;54:453-6.
79. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54:547-70.
80. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6.
81. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252: 3578-81.
82. Maeda H, Ueda M, Morinaga T, Matsumoto T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem 1985;28:455-61.
83. Maeda H. Smancs and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 1991;6: 181-202.
84. Maeda HaK, T. Metamorphosis of neocarzinostatin to smancs: chemistry, biology, pharmacology, and clinical effect of the first prototype anticancer polymer therapeutic. Tokyo, Berlin, New York: Springer Verlag; 1997:227-67.
85. Kunimasa JI, Itoga Y, Yasuhara M, et al. Pharmacokinetics and pharmacological effect of recombinant human granulocyte colonystimulating factor conjugated to poly(styrene-co-maleic acid) in rats. J Pharm Pharmacol 1999;51:777-82.
86. Mu Y, Kamada H, Kaneda Y, et al. Bioconjugation of laminin peptide yigsr with poly(styrene co-maleic acid) increases its antimetastatic effect on lung metastasis of b16-bl6 melanoma cells. Biochem Biophys Res Commun 1999;255:75-9.
87. Ogino T, Inoue M, Ando Y, et al. Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin. Int J Peptide Protein Res 1988;32:153-9.
88. Kobayashi A, Oda T, Maeda H. Protein binding of macromolecular anticancer agent smancs: characterization of poly(styreneco-maleic acid) derivatives as an albumin binding ligand. J Bioactive Compatible Polymers 1988;3:319-33.
89. Yi X, Batrakova E, Banks WA, et al. Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery. Bioconjug Chem 2008;19:1071-7.
90. Yi X. Protein modification by pluronic block copolymer for brain delivery [thesis]. University of Nebraska Medical Center; 2010.
91. Yi X, Zimmerman MC, Yang R, et al. Pluronic-modified superoxide dismutase 1 attenuates angiotensin ii-induced increase in intracellular superoxide in neurons. Free Radical Biol Med 2010; 49:548-58.
92. Price TO, Farr SA, Yi X, et al. Transport across the blood-brain barrier of pluronic leptin. J Pharmacol Exp Ther 2010;333:253-63.
93. Tong J, Luxenhofer R, Yi X, et al. Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery. Mol Pharm 2010;7:984-92.
94. Tong J, Yi X, Luxenhofer R, et al. Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo. Mol Pharm 2013;10:360-77.
95. Cellesi F. Thermoresponsive hydrogels for cellular delivery. Ther Deliv 2012;3:1395-407.
96. Florence AT, Whitehill D. Stabilization of water/oil/water multiple emulsions by polymerization of the aqueous phases. J Pharm Pharmacol 1982;34:687-91.
97. Forster D, Washington C, Davis SS. Toxicity of solubilized and colloidal amphotericin b formulations to human erythrocytes. J Pharm Pharmacol 1988;40:325-8.
98. Jung YW, Lee H, Kim JY, et al. Pluronic-based core/shell nanoparticles for drug delivery and diagnosis. Curr Med Chem 2013;20:3488-99.
99. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002;19:1-72
100. Chen YC, Hsieh WY, Lee WF, Zeng DT. Effects of surface modification of plga-peg-plga nanoparticles on loperamide delivery efficiency across the blood-brain barrier. J Biomater Appl 2013;27:909-22
101. Gelperina S, Maksimenko O, Khalansky A, et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 2010;74:157-63
102. Kulkarni SA, Feng SS. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond) 2011;6:377-94
103. Kabanov AV, Chekhonin VP, Alakhov V, et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett 1989;258:343-5
104. Kabanov AV, Batrakova EV, Melik-Nubarov NS, et al. A new class of drug carriers: Micelles of poly (oxyethylene)-poly (oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J Control Release 1992;22: 141-58
105. Miller DW, Batrakova EV, Waltner TO, et al. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem 1997;8:649-57
106. Batrakova EV, Han HY, Miller DW, Kabanov AV. Effects of pluronic p85 unimers and micelles on drug permeability in polarized bbmec and caco-2 cells. Pharm Res 1998;15: 1525-32
107. Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic p85 increases permeability of a broad spectrum of drugs in polarized bbmec and caco-2 cell monolayers. Pharm Res 1999;16: 1366-72
108. Batrakova EV, Miller DW, Li S, et al. Pluronic p85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001;296:551-7
109. Batrakova EV, Li S, Alakhov VY, et al. Optimal structure requirements for pluronic block copolymers in modifying p-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 2003;304: 845-54
110. Nametkin SN, AK LD, Kabanov AV, Levashov AV. Modulation of membrane activity of an enzyme in reversed micelle system with a change of media ph (using alkaline phosphatase as an example). Bioorganicheskaia Khimiia 1992;18:777-83
111. Sahay G, Batrakova EV, Kabanov AV. Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. Bioconjug Chem 2008;19:2023-9
112. Sahay G, Gautam V, Luxenhofer R, Kabanov AV. The utilization of pathogen-like cellular trafficking by single chain block copolymer. Biomaterials 2009;31:1757-64
113. Ding Y, Li YL, Zimmerman MC, et al. Role of cuzn superoxide dismutase on carotid body function in heart failure rabbits. Cardiovasc Res 2009;81:678-85
114. Gao L, Wang W, Li YL, et al. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin ii and nad(p)h oxidase. Circ Res 2004;95:937-44
115. Gao L, Wang W, Liu D, Zucker IH. Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure. Circulation 2007;115: 3095-102
116. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. Auton Neurosci 2008;142:20-4
117. Zimmerman MC, Lazartigues E, Lang JA, et al. Superoxide mediates the actions of angiotensin ii in the central nervous system. Circulation Res 2002;91:1038-45
118. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin ii infusion involves increased superoxide production in the central nervous system. Circulation Res 2004;95:210-16
119. Banks WA, Kastin AJ, Huang W, et al. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996;17: 305-11
120. Levin BE, Dunn-Meynell AA, Banks WA. Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am J Physiol 2004;286: R143-50
121. Schwartz MW, Woods SC, Porte Jr D, et al. Central nervous system control of food intake. Nature 2000;404:661-71
122. Wu-Peng XS, Chua Jr SC, Okada N, et al. Phenotype of the obese koletsky (f) rat due to tyr763stop mutation in the extracellular domain of the leptin receptor (lepr): evidence for deficient plasmato-csf transport of leptin in both the zucker and koletsky obese rat. Diabetes 1997;46:513-18
123. Yi X, Yuan D, Banks WA, Kabanov AV. Leptin analogs overcome leptin peripheral resistance and control appetite in diet induced obese mice Keystone Symposia on Molecular and Cellular Biology, Neuronal Control of Appetite, Metabolism and Weight; 2012; Fairmont Banff Springs, Banff, Alberta, Canada
124. Zhang X, Alakhova DY, Batrakova EV, et al. Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells. J Neuroimmune Pharmacol 2009;4:35-46
125. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999;20:1341-5
126. Batrakova EV, Li S, Li Y, et al. Distribution kinetics of a micelleforming block copolymer pluronic p85. J Control Release 2004; 100:389-97
127. Dodelet-Devillers A, Cayrol R, van Horssen J, et al. Functions of lipid raft membrane microdomains at the blood-brain barrier. J Mol Med (Berl) 2009;87:765-74
128. Manes S, Mira E, Gomez-Mouton C, et al. Membrane raft microdomains mediate front-rear polarity in migrating cells. EMBO J 1999;18:6211-20
129. Mero A, Pasut G, Dalla Via L, et al. Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to peg-conjugates? J Control Release 2008;125:87-95
130. Viegas TX, Bentley MD, Harris JM, et al. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem 2011;22:976-86
131. Moreadith RWVT, Standaert DG, Bentley MD, et al. Ser-214, a novel polymer-conjugated rotigotine formulation affords greatly extended duration of anti-parkinsonian effect and enhanced plasma exposure following a single administration in rodents and primates. 16th International Conference of Parkinson's Disease and Movement Disorders; 2012; Dublin, Ireland
132. Luxenhofer R, Han Y, Schulz A, et al. Poly(2-oxazoline)s as polymer therapeutics. Macromol Rapid Commun 2012;33: 1613-31
133. Luxenhofer R, Schulz A, Roques C, et al. Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials 2010;31:4972-9
134. Luxenhofer R, Sahay G, Schulz A, et al. Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles. J Control 2011;153:73-82.
135. Schmolka I. A review of block polymer surfactants. J Amer Oil Chem Soc 1977;54:110-16.